Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Trump’s Plans for Pharma Industry Gain Support of CEOs



The aftermath of the meeting left many pharmaceutical executives feeling optimistic.

Share this!

February 3, 2017 | by Sarah Hand, M.Sc.

Though President Donald Trump’s remarks on controlling drug prices may have initially scared pharmaceutical companies, his newest plans are music to their ears. On Tuesday, Trump met with pharmaceutical industry leaders where he vowed to reduce regulations, expedite US Food and Drug Administration (FDA) approvals and get drugmakers to start manufacturing their products on US soil.

The aftermath of the meeting left many pharmaceutical executives feeling optimistic. The proposals could encourage major growth within the industry, and might even help create new jobs. CEO of the trade organization PhRMA, tweeted: “We believe @POTUS agenda on taxes, trade & regulations could create 350,000 American jobs over 10 years due to biopharma industry growth 2/3.”

According to an article published by FiercePharma, Pfizer CEO Ian Read was unable to attend the meeting with Trump, however he did make a statement about the proposed changes in the company’s Q4 earnings call. “I think we can be a very positive part of the story of creating jobs in the United States if we get the tax reform,” said Read.

In an interview with CNBC, Eli Lilly CEO David Ricks said that he felt the President Trump “clearly understood and was listening to the message of innovation.” He went on to say that Eli Lilly is ready to “work with the White House and Capitol Hill over the coming months to look at some more market-based solutions to help consumers.”

While Trump’s message seems to have changed, some are wary of his ideas on speeding up drug approvals. “Millions of Americans across the country rely on the FDA to ensure that the drugs that they take each day are safe and effective,” said US Representative Rosa DeLauro. “These regulations are in place for a reason.”

While drug pricing seems to have taken a back seat to other issues in the industry, analysts say the debate could flare up again in the coming months. According to Read, there are “lots of ways we can work with the administration to ensure that patients have affordable drugs.”

Keywords: Pharmaceutical Industry, FDA, Trump


Share this with your colleagues!

Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News

New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News

Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub


Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases

Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects

Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance

Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned

Copyright © 2016-2017 Honeycomb Worldwide Inc.